AI PRICE FORECAST
GILD Stock Forecast & AI Price Prediction
Gilead Sciences · Healthcare · Drug Manufacturers - General
GILD live signal snapshot
GILD last traded at $169.73, down 0.67% on the session, trading 3.9% below its 52-week high of $176.58 and 45.2% above its 52-week low of $116.88. Stock Pulse 247's AI model currently rates GILD a BUY, at 71% model confidence. Short-term moving averages are mixed right now, without a clean bullish or bearish stack forming yet. The model's one-month path points toward roughly $175.61 (3.5% from here).
On the 14-day relative strength index, GILD reads 68.2, showing buyers in control without the stretch of an overbought reading. Its MACD line is above its signal line with a positive histogram (0.29) — upward momentum is accelerating. Its 50-day average ($154.40) is holding 9.2% above the 200-day ($141.44), the pattern chartists call a golden cross.
The average 12-month target from 26 Wall Street analysts is $174.77 (range $131.00–$200.00) — 3.0% upside from where GILD trades now. The current recommendation trend leans bullish: 22 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 5 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive GILD dashboard for numbers updated throughout today's session.
About Gilead Sciences
Gilead Sciences, Inc. (GILD) is a drug manufacturers - general company in the healthcare sector, headquartered in Foster City, CA, United States. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. It has a market value of about $210.5 billion and roughly 17,000 full-time employees. With a beta of 0.37, the stock has historically moved less than the overall market.
GILD performance vs. the market
GILD is up 38.3% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 43.7%, 32.2 points better than the S&P 500. The last month (+14.7%) continues the three-month advance (+22.9%).
| Period | GILD | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +14.7% | +11.4% | −2.3% |
| 3 months | +22.9% | +12.2% | −2.3% |
| Year to date | +38.3% | +22.1% | +11.4% |
| 1 year | +43.7% | +28.3% | +11.5% |
Gilead Sciences financials at a glance
In the quarter ended Sep 30, 2026, Gilead Sciences reported revenue of $8.3 billion and net income of $2.4 billion (a 29.3% net margin). Revenue was up 6.8% from the same quarter a year earlier. The stock trades at trailing earnings of $-3.13 per share. Trailing free cash flow was $10.7 billion, and total debt equals 203% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $8.3B | $2.4B |
| Jun 30, 2026 | $7.8B | −$10.5B |
| Mar 31, 2026 | $7.0B | $2.0B |
| Dec 31, 2025 | $7.9B | $2.2B |
GILD vs. its peers
Against 5 of its largest healthcare peers, GILD's +38.3% year-to-date return beats 3 of them. The strongest of the group this year is Amgen (AMGN, +43.0%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Gilead Sciences (GILD) | $169.73 | +38.3% | — | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
GILD stock: common questions
What is the GILD stock price target?
26 Wall Street analysts put the average 12-month target at $174.77, in a range of $131.00–$200.00, versus a recent price of $169.73. Stock Pulse 247's model projects about $175.61 over the next month.
Is GILD a buy right now?
Our AI model currently rates GILD a BUY at 71% confidence. Among analysts, 22 rate it Buy or Strong Buy, 5 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has GILD stock performed this year?
GILD is up 38.3% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 43.7%, 32.2 points better than the S&P 500. The last month (+14.7%) continues the three-month advance (+22.9%).
What is GILD's 52-week high and low?
GILD has traded between $116.88 and $176.58 over the past 52 weeks; at $169.73 it is 3.9% below its 52-week high of $176.58 and 45.2% above its 52-week low of $116.88.
What sector is GILD in, and who are its peers?
GILD is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the GILD forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines GILD's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.